Amicus Therapeutics

Inactive

FOLD (NasdaqGM)

Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for rare diseases in the U.S. and internationally. Its programs include Galafold, an oral monotherapy for adults with Fabry disease due to an amenable variant; Pombiliti plus Opfolda for late-onset Pompe disease; and DMX-200, a CXCR2 inhibitor in Phase 3 for focal segmental glomerulosclerosis. It partners with GlaxoSmithKline and Dimerix. Incorporated in 2002, based in Princeton, NJ.